VEGF with AMD3100 endogenously mobilizes mesenchymal stem cells and improves fracture healing

被引:19
|
作者
Meeson, Richard [1 ,2 ]
Sanghani-Keri, Anita [1 ]
Coathup, Melanie [1 ,3 ]
Blunn, Gordon [1 ,4 ]
机构
[1] Univ Coll London, Div Surg, Stanmore, Middx, England
[2] Royal Vet Coll, Hatfield, Herts, England
[3] Univ Cent Florida, Orlando, FL 32816 USA
[4] Univ Portsmouth, Portsmouth, Hants, England
基金
英国医学研究理事会;
关键词
mobilization; mesenchymal stem cells; AMD3100; VEGF; fracture healing; BONE-MARROW; PERIPHERAL-BLOOD; PROGENITOR CELLS; IN-VIVO; BIOLOGICAL CHARACTERISTICS; PRECURSOR CELLS; ANGIOGENESIS; MIGRATION; REPAIR; ANTAGONIST;
D O I
10.1002/jor.24164
中图分类号
R826.8 [整形外科学]; R782.2 [口腔颌面部整形外科学]; R726.2 [小儿整形外科学]; R62 [整形外科学(修复外科学)];
学科分类号
摘要
A significant number of fractures develop non-union. Mesenchymal stem cell (MSC) therapy may be beneficial, however, this requires cell acquisition, culture and delivery. Endogenous mobilization of stem cells offers a non-invasive alternative. The hypothesis was administration of VEGF and the CXCR4 antagonist AMD3100 would increase the circulating pool of available MSCs and improve fracture healing. Ex-breeder female wistar rats received VEGF followed by AMD3100, or sham PBS. Blood prepared for culture and colonies were counted. P3 cells were analyzed by flow cytometry, bi-differentiation. The effect of mobilization on fracture healing was evaluated with 1.5 mm femoral osteotomy stabilized with an external fixator in 12-14 week old female Wistars. The mobilized group had significantly greater number of cfus/ml compared to controls, p = 0.029. The isolated cells expressed 1.8% CD34, 35% CD45, 61% CD29, 78% CD90, and differentiated into osteoblasts but not into adipocytes. The fracture gap in animals treated with VEGF and AMD3100 showed increased bone volume; 5.22 +/- 1.7 mu m(3) and trabecular thickness 0.05 +/- 0.01 mu m compared with control animals (4.3 +/- 3.1 mu m(3), 0.04 +/- 0.01 mu m, respectively). Radiographic scores quantifying fracture healing (RUST) showed that the animals in the mobilization group had a higher healing score compared to controls (9.6 vs. 7.7). Histologically, mobilization resulted in significantly lower group variability in bone formation (p = 0.032) and greater amounts of bone and less fibrous tissue than the control group. Clinical significance: This pre-clinical study demonstrates a beneficial effect of endogenous MSC mobilization on fracture healing, which may have translation potential to prevent or treat clinical fractures at risk of delayed or non-union fractures. (c) 2018 The Authors. Journal of Orthopaedic Research (R) Published by Wiley Periodicals, Inc. on behalf of Orthopaedic Research Society. J Orthop Res 37:1294-1302, 2019.
引用
收藏
页码:1294 / 1302
页数:9
相关论文
共 50 条
  • [31] The combination of G-CSF and AMD3100 mobilizes bone marrow-derived stem cells to protect against cisplatin-induced acute kidney injury in mice
    Zhi Chen
    Xiang Ren
    Ruimin Ren
    Yonghong Wang
    Jiwen Shang
    Stem Cell Research & Therapy, 12
  • [32] The combination of G-CSF and AMD3100 mobilizes bone marrow-derived stem cells to protect against cisplatin-induced acute kidney injury in mice
    Chen, Zhi
    Ren, Xiang
    Ren, Ruimin
    Wang, Yonghong
    Shang, Jiwen
    STEM CELL RESEARCH & THERAPY, 2021, 12 (01)
  • [33] AMD3100 synergizes with G-CSF to mobilize repopulating stem cells in Fanconi anemia knockout mice
    Pulliam, Anna C.
    Hobson, M. Joe
    Ciccone, Samantha L.
    Li, Yan
    Chen, Shi
    Srour, Edward F.
    Yang, Feng-Chun
    Broxmeyer, Hal E.
    Clapp, D. Wade
    EXPERIMENTAL HEMATOLOGY, 2008, 36 (09) : 1084 - 1090
  • [34] Rapid mobilization of fully functional natural killer cells into blood by AMD3100
    Sheng, Lixia
    Fu, Shan
    Hu, Yongxian
    Fu, Huarui
    Huang, He
    TRANSFUSION, 2013, 53 (09) : 2108 - 2110
  • [35] The CXCR4 antagonist AMD3100 stimulates the proliferation of myeloma cells
    Kim, H. Y.
    Kim, S. W.
    Lee, H. J.
    Yun, H. J.
    Kim, S.
    Jo, D. Y.
    BONE MARROW TRANSPLANTATION, 2008, 41 : S178 - S178
  • [36] The CXCR4 Antagonist AMD3100 Stimulates the Proliferation of Myeloma Cells
    Kim, Ha-Yon
    Kim, Seong-Woo
    Lee, Hyo-Jin
    Yun, Hwan-Jung
    Kim, Samyong
    Jo, Deog-Yeon
    BLOOD, 2008, 112 (11) : 600 - 601
  • [37] Rapid mobilization of murine and human hematopoietic stem and progenitor cells with AMD3100, a CXCR4 antagonist
    Broxmeyer, HE
    Orschell, CM
    Clapp, DW
    Hangoc, G
    Cooper, S
    Plett, PA
    Liles, WC
    Li, XX
    Graham-Evans, B
    Campbell, TB
    Calandra, G
    Bridger, G
    Dale, DC
    Srour, EF
    JOURNAL OF EXPERIMENTAL MEDICINE, 2005, 201 (08): : 1307 - 1318
  • [38] The Combination of Groβt and AMD3100 Leads to Rapid and Robust Mobilization of Hematopoietic Stem Cells in Nonhuman Primates
    Falahee, Patrick
    Goncalves, Kevin A.
    Hyzy, Sharon L.
    Proctor, Jennifer L.
    Hoggatt, Jonathan
    Morrow, Dwight
    Cooke, Michael P.
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2018, 24 (03) : S424 - S424
  • [39] CXCR4 Antagonist AMD3100 Accelerates Impaired Wound Healing in Diabetic Mice
    Nishimura, Yukihide
    Ii, Masaaki
    Qin, Gangjian
    Hamada, Hiromichi
    Asai, Jun
    Takenaka, Hideya
    Sekiguchi, Haruki
    Renault, Marie-Ange
    Jujo, Kentaro
    Katoh, Norito
    Kishimoto, Saburo
    Ito, Aiko
    Kamide, Christine
    Kenny, John
    Millay, Meredith
    Misener, Sol
    Thorne, Tina
    Losordo, Douglas W.
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2012, 132 (03) : 711 - 720
  • [40] Plerixafor (AMD3100) in myeloma and lymphoma patients undergoing autologous stem cell transplantation
    Moreb, J. S.
    Salmasinia, D.
    Cline, C.
    Rosenau, E.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)